Merck (MRK) is close to a deal to buy lung disease-focused biotech Verona Pharma (VRNA) for roughly $10B, The Financial Times’ Oliver Barnes reports. An acquisition of Verona would be Merck’s largest since its $10.8B takeover of Prometheus Biosciences in 2023, Barnes notes. As part of the deal, Merck would pay $107 per American depository share for Verona, a 23% premium to the biotech’s closing price on Tuesday, according to three people familiar with the matter. A deal could be announced as soon as Wednesday, according to the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Cautious Outlook on Merck & Company Amid International Sales Challenges for Gardasil and Keytruda
- M&A News: Merck Strikes $10B Deal to Buy Verona Pharma
- Mixed options sentiment in Merck with shares up 1.58%
- Drugmakers criticize Trump drug price negotiation plan, Bloomberg reports
- Pharma cos criticize Trump’s drug price negotiation plan, Bloomberg Law reports